Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 701-269-3 | CAS number: -
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Description of key information
In a screening study for reproductive/developmental effects performed with the read-across substance bisamide (UVCB) according to OECD Guideline 421 in compliance with GLP, the objective was to evaluate the potential toxic effects of the test substance following daily oral administration (gavage) to male and female rats from before mating, through mating and gestation until Day 6post-partum. Three groups of 10 male and 10 female rats received the test substance by gavage at doses of 100, 300 or 1,000 mg/kg bw/day. Males were treated for 15 days before pairing, up to the day before necropsy after a minimum treatment period of five consecutive weeks. Females were treated daily for a minimum of 15 days before pairing, throughout mating and gestation until Day 6 of lactation. A similarly constituted control group received the vehicle, corn oil, at the same volume-dose. During the study, clinical condition, bodyweight, food consumption, organ weights, macroscopic and microscopic pathology investigations were undertaken in all adults. Oestrous cycles and gestation length were assessed and parturition observations were performed for females. The clinical condition, litter size and survival, sex ratio and bodyweight of all offspring were assessed and macroscopic pathology investigations were undertaken. There were no deaths, and the general appearance and behaviour of the animals were not affected by treatment. There were no adverse effects of treatment on adult bodyweights, bodyweight gains or food consumption and no effects on oestrous cycles, pre-coital interval, mating performance, fertility, conception rate or fertility index; gestation length and gestation index. At 1,000 mg/kg bw/day, the post-implantation survival index was slightly decreased compared to controls (86.1 versus 94.4% in controls). However, this slightly low value remained in the historical range of the laboratory (84.9 to 100%). As a consequence, the mean live litter size on Day 1 was slightly lower than in controls (14.3 versus 15.1 in controls). There were no effects of treatment on offspring survival and sex ratio and offspring bodyweight gain to Day 7 of age. There were no macro-pathological findings in the adults or offspring. Analysis of the weight of the selected organs at scheduled termination revealed statistically significant increased prostate weight for males receiving 1,000 mg/kg bw/day. The weight of all other selected organs was unaffected by treatment and there were no particular microscopic findings. It was concluded that the NOAEL for the test substance was 1,000 mg/kg bw/day for reproductive performance and offspring growth and survival in the CD rat following oral gavage administration in a standard screening test.
Link to relevant study records
- Endpoint:
- screening for reproductive / developmental toxicity
- Remarks:
- based on generations indicated in Effect levels (migrated information)
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- From 20 july 2012 to 04 january 2013
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Read across study hence maximum reliability rating of 2 assigned according to ECHA guidance.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 421 (Reproduction / Developmental Toxicity Screening Test)
- Deviations:
- yes
- Remarks:
- Necropsies for the males were scheduled for Week 6 of treatment instead of Week 5. The OECD 421 guideline requires a necropsy of the males after a dosing period of at least 4 weeks. Therefore this deviation did not affect the the integrity of the study.
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
- Species:
- rat
- Strain:
- Crj: CD(SD)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River (UK) Ltd.
- Age at study initiation: 10 weeks
- Weight at study initiation: 344 to 386 g (males) and 241 to 278 g (females)
- Fasting period before study:no
- Housing: Females: 5 per cage during pre-pairing then individually housed except during pairing,
Males: 5 per cage except during pairing,
- Diet: Ad libitum, standard rodent diet (SDS VRF1 Certified). This diet contained no added antibiotic or other chemotherapeutic or prophylactic agent
- Water: Ad libitum, potable water taken from the public supply.
- Acclimation period: 5 days
ENVIRONMENTAL CONDITIONS
- Temperature: 19 to 23°C
- Humidity: 40 to 70%
- Air changes (per hr): Each animal room was kept at positive pressure with respect to the outside by its own supply of filtered fresh air, which was passed to atmosphere and not re-circulated
- Photoperiod (hrs dark / hrs light): 12 h continuous light and 12 h continuous dark/24 h. - Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
VEHICLE
- Justification for use and choice of vehicle (if other than water): homogeneous and stable suspensions were obtained with corn oil as a vehicle
- Concentration in vehicle: 20, 60 and 200 mg/ml
- Amount of vehicle (if gavage): 5 ml/kg bw - Details on mating procedure:
- - M/F ratio per cage: 1/1
- Length of cohabitation (mating period): until mating occurs or 14 days has elapsed
- Proof of pregnancy: vaginal plug or sperm in the morning vaginal lavage referred to as day 0 of gestation
- After successful mating each pregnant female was caged individually. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Homogeneity and stability of the dosage forms: homogeneity of the test substance in corn oil formulations was assessed with respect to the level of concentration at nominal concentrations of 10 mg/mL and 200 mg/mL. Homogeneity was confirmed during distribution between the bottles, during magnetic stirring for 2 hours, and on re-suspension following storage at ambient temperature for 1 day and refrigeration for up to 15 days. At each time-point, the mean analysed concentration for the three samples remained within 7% of the initial time zero value and the coefficient of variation was less than 4%.
Test item concentrations: the test item concentrations in the administered dosage forms analyzed in the first and last weeks of treatment remained within an acceptable range of +10% to -15% when compared to the nominal values. - Duration of treatment / exposure:
- In the males:
− 2 weeks before mating,
− during the mating period (up to 2 weeks),
− until sacrifice in week 6,
In the females:
− 2 weeks before mating,
− during the mating period (up to 2 weeks),
− during pregnancy,
− during lactation until day 6 post-partum inclusive - Frequency of treatment:
- daily
- Details on study schedule:
- - No F1 parents (only one generation mated)
- Age at mating of the mated animals in the study: 13 weeks for males, 13 weeks for females, approximately. - Remarks:
- Doses / Concentrations:
0, 100, 300 and 1,000 mg/kg bw/day
Basis:
other: nominal doses - No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale:
The dose-levels used in this study (0, 100, 300 and 1000 mg/kg/day) were selected on the basis of the results of a 14-day repeated- dose preliminary study in the CD rat. In that study, the substance was generally well tolerated at dose levels up to 1000 mg/kg/day with no noteworthy effect of treatment on clinical signs, bodyweight gain, food consumption, macroscopic findings or organ weights. - Positive control:
- none
- Parental animals: Observations and examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily
DETAILED CLINICAL OBSERVATIONS: Yes
-detailed physical examination was performed weekly. F0 females were also examined on Days 0, 7, 14 and 20 after mating and on Days 1 and 7 of lactation to monitor general health.
BODY WEIGHT: Yes
- Time schedule for examinations: The weight of each adult was recorded during acclimatisation, on the day that treatment commenced (Week 0), weekly thereafter and before necropsy. The weight of each F0 female was also recorded on Days 0, 3, 7, 10, 14, 17 and 20 after mating and on Days 1, 4 and 7 of lactation.
FOOD CONSUMPTION :
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
The weight of food supplied to each cage, that remaining and an estimate of any spilled was recorded on a weekly basis from the first day of treatment until pairing. From these records the mean weekly consumption per animal (g/rat/week) was calculated for each cage.
For each F0 female, the weight of food supplied, that remaining and an estimate of any spilled was also recorded for the periods Days 0-2, 3-6, 7-9, 10-13, 14-16 and 17-19 after mating and Days 1-3 and 4-6 of lactation. From these records the mean daily consumption (g/rat/day) was calculated for each animal.
WATER CONSUMPTION: No - Oestrous cyclicity (parental animals):
- For 15 days before pairing, daily vaginal smears were taken from all females. The smears were subsequently examined to establish the duration and regularity of the oestrous cycle. After pairing with the male, smearing was continued using pipette lavage, until evidence of mating was observed.
- Sperm parameters (parental animals):
- Parameters examined in males of parental generation:
- testis weight (all groups) + microscopic evaluation (all groups)
- epididymis weight (all groups) + microscopic evaluation (control and high-dose groups)
- microscopic evaluation of stages of the spermatogenic cycle and testicular interstitial cells (control and high-dose groups)
- detailed qualitative examination was made of the testes, taking into account the tubular stages of the spermatogenic cycle. The examination was conducted in order to identify treatment related effects such as missing germ cell layers or types, retained spermatids, multinucleate or apoptotic germ cells and sloughing of spermatogenic cells into the lumen. Any cell- or stage-specificity of testicular findings was noted. - Litter observations:
- STANDARDISATION OF LITTERS: No
PARAMETERS EXAMINED:
- number and sex of pups,
- number of live, dead and cannibalized pups,
- presence of gross anomalies, weight gain, clinical signs
GROSS EXAMINATION OF DEAD AND SURVIVING PUPS:
- external and internal abnormalities. - Postmortem examinations (parental animals):
- SACRIFICE
The males were sacrificed during week 6 of treatment. The body and selected organs were weighed and a complete macroscopic post-mortem examination was performed. A microscopic examination was performed on the kidneys, liver and epididymis from the males in the control- and high dose groups, testes from all groups and on all macroscopic lesions.
The dams were sacrificed on day 7 of lactation, the body and selected organs were weighed and a complete macroscopic examination was performed.
A microscopic examination was performed on the kidneys, liver and ovaries in the control and high-dose groups and on all macroscopic lesions.
GROSS NECROPSY
On completion of the treatment period all surviving F0 males and females were killed by carbon dioxide asphyxiation.
- males: after the end of the pairing period (during week 6 of treatment ),
- females: on day 7of lactation.,
- females which had not delivered: on day 25 after mating (after a body weight recording to check for a possible un-noticed delivery),
- mothers with litter dying entirely: as appropriate.
For females, the numbers of implantation sites in each uterine horn was counted. For females failing to produce a viable litter, the number of uterine implantation sites was re-checked after staining with ammonium sulphide (modification of the Salewski staining technique).
Pups were sacrificed by an intraperitoneal injection of sodium pentobarbital:
- surviving pups: on day7 of age.
- Premature deaths if not autolysed or cannibalised.
HISTOPATHOLOGY
A microscopic examination was performed on:
- Liver, kidneys,epididymides and ovaries in animals of the control- and high-dose groups sacrificed at the end of the treatment period and for female that were sacrificed prematurely,
- all macroscopic lesions of all the animals of the low- and intermediate-dose groups sacrificed on completion of the treatment
period,
- Testes of males from control, low-, mid- and high-dose groups,
Special emphasis was paid to the stages of spermatogenesis in the male gonads and histopathology of interstitial testicular cell structure.
ORGAN WEIGHTS:
The body weight of each animal sacrificed as scheduled was recorded before sacrifice, and liver, kidney,epididymides (L and R), prostate, testes (L and R), seminal vesicles and ovaries (L and R) were weighed (wet) as soon as possible after dissection.The ratio of organ weight to body weight (recorded immediately before sacrifice) was calculated. - Postmortem examinations (offspring):
- SACRIFICE: on day 7 of age
GROSS NECROPSY: on all pups (surviving and found dead)
HISTOPATHOLOGY: No
ORGAN WEIGTHS: No - Statistics:
- - For all other adult parameters, the analyses were carried out using the individual animal as the basic experimental unit.
- For litter/fetal findings the litter was taken as the treated unit and the basis for statistical analysis and biological significance was assessed with relevance to the severity of the anomaly and the incidence of the finding within the background control population.
# The following sequence of statistical tests was used for bodyweight, food consumption, organ weights and litter data:
A parametric analysis was performed if Bartlett's test for variance homogeneity was not significant at the 1% level. The F1 approximate test was applied. If the F1 approximate test was not significant at the 1% level, Williams' test was applied. If the F1 approximate test was significant, suggesting that the dose response was not monotone, Dunnett's test was performed instead.
A non-parametric analysis was performed if Bartlett's test was still significant at the 1% level following both logarithmic and square-root transformations. The H1 approximate test was applied. If the H1 approximate test was not significant at the 1% level, Shirley's test was applied. If the H1 approximate test was significant, suggesting that the dose-response was not monotone, Steel's test was performed instead.
For litter data if 75% of the data (across all groups) were the same value, for example c, Fisher’s Exact tests were performed. Treatment groups were compared using pairwise comparisons of each dose group against the control both for i) valuesc, as applicable.
# For organ weight data, analysis of covariance was performed using terminal bodyweight as covariate, unless non-parametric methods were applied.
# Sex ratio were analysed by generalised mixed linear model with binomial errors. - Reproductive indices:
- Percentage Mating = 100 * (Number animals mating/animals paired)
Fertility index = 100 * (Number animals achieving pregnancy / Number of animals mated)
Gestation index = 100 * (Number of live litters born / Number pregnant) - Offspring viability indices:
- - Post-implantation survival index= 100 * (Number of pups born / Number of uterine implantation sites)
Post-implantation survival index was expressed as 100% where the number of offspring exceeded the number of implantation sites recorded.
- Live birth index = 100 * (Number of live born pups on Day 1/ Number of delivered pups)
- Viability index = 100 * (Number of surviving pups on day 7 / Number of live born pups on Day 1) - Clinical signs:
- no effects observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Other effects:
- not examined
- Reproductive function: oestrous cycle:
- no effects observed
- Reproductive function: sperm measures:
- no effects observed
- Reproductive performance:
- no effects observed
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- Reproductive performance
- Effect level:
- >= 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- reproductive performance
- Clinical signs:
- no effects observed
- Mortality / viability:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Sexual maturation:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- no effects observed
- Histopathological findings:
- not examined
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- Developmental toxicity
- Generation:
- F1
- Effect level:
- >= 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: offspring growth and survival
- Key result
- Reproductive effects observed:
- no
- Conclusions:
- It was concluded that the No-Observed-Adverse-Effect-Level (NOAEL) was 1000 mg/kg/day (the top dose) for reproductive performance and offspring growth and survival in the CD rat following oral gavage administration in a standard screening test.
- Executive summary:
In a screening study for reproductive / developmental effects performed according to OECD 421 , the objective was to evaluate the potential toxic effects of the test substance following daily oral administration (gavage) to male and female rats from before mating, through mating and gestation until Day 6 post-partum.
Three groups of 10 male and 10 female rats received the test substance by gavage at doses of 100, 300 or 1000 mg/kg/day. Males were treated for 15 days before pairing up to the day before necropsy after a minimum treatment period of five consecutive weeks. Females were treated daily for a minimum of 15 days before pairing, throughout mating and gestation until Day 6 of lactation. A similarly constituted Control group received the vehicle, corn oil, at the same volume-dose.
During the study, clinical condition, bodyweight, food consumption, organ weights, macroscopic and microscopic pathology investigations were undertaken in all adults. Oestrous cycles and gestation length were assessed and parturition observations were performed for females. The clinical condition, litter size and survival, sex ratio and bodyweight of all offspring were assessed and macroscopic pathology investigations were undertaken.
There were no deaths, and the general appearance and behaviour of the animals were not affected by treatment. There were no adverse effects of treatment on adult bodyweights, bodyweight gains or food consumption and no effects on oestrous cycles, pre-coital interval, mating performance, fertility, conception rate or fertility index; gestation length and gestation index.
At 1000 mg/kg/day, the post-implantation survival index was slightly decreased compared to controls (86.1% versus 94.4% in controls). However, this slightly low value remained in the historical range of the laboratory (84.9% to 100%). As a consequence, the mean live litter size on Day 1 was slightly lower than in controls (14.3 versus 15.1 in controls).
There were no effects of treatment on offspring survival and sex ratio and offspring bodyweight gain to Day 7 of age. There were no macropathological findings in the adults or offspring. Analysis of the weight of the selected organs at scheduled termination revealed statistically significant increased prostate weight for males receiving 1000 mg/kg/day. The weight of all other selected organs was unaffected by treatment with Bisamide 80005005 and there were no particular microscopic findings.
It was concluded that the NOAEL for the test substance was 1000 mg/kg/day (the limit dose) for reproductive performance and offspring growth and survival in the CD rat following oral gavage administration in a standard screening test.
Reference
There were no deaths and no particular clinical signs.
BODY WEIGHT AND FOOD CONSUMPTION (PARENTAL ANIMALS)
There was no effect of treatment on mean bodyweight gain and foood consumption of all groups of males receiving the test substance. Overall bodyweight, bodyweight change and food consumption of females receiving the test substance at 100, 300 or 1000 mg/kg/day were lower than that of the Controls during the first week of treatment although a dose response was not apparent. There was no conclusive effect of treatment during the second week of treatment, and weight gain and food consumption throughout Days 1-7 of lactation was similar in all groups.
REPRODUCTIVE FUNCTION: ESTROUS CYCLE (PARENTAL ANIMALS)
Oestrous cycle length was unaffected by treatment.
REPRODUCTIVE FUNCTION: SPERM MEASURES (PARENTAL ANIMALS)
- There was no effect of treatment on the weight of testes and epididymides.
REPRODUCTIVE PERFORMANCE (PARENTAL ANIMALS)
Mating performance and fertility as assessed by percentage mating, conception rate and fertility index, were unaffected by treatment.
ORGAN WEIGHTS (PARENTAL ANIMALS)
Statistically significant increased prostate weight for males receiving the test substance at 1000 mg/kg/day was noted. As the prostate was not assessed microscopically, the toxicological significance of these slight increases was uncertain, however in the absence of any effects on fertility or reproductive performance, in isolation these changes were considered not to be adverse.
GROSS PATHOLOGY (PARENTAL ANIMALS)
There were no findings at macroscopic examination that could be attributed to treatment with the test substance.
HISTOPATHOLOGY (PARENTAL ANIMALS)
- Slight to minimal bilateral tubular atrophy, with partial or complete depletion of germ cells from a few scattered tubules, was respectively seen at
300 mg/kg/day in 1 animal and at 1000 mg/kg/day in 2 animals. In the epididymides minimal amounts of degenerated spermatogenic cells in the ducts were also observed in the two males treated with 1000 mg/kg/day and were considered secondary to the changes seen in the testes.
Although the distribution pattern was suggestive of a treatment effect, these changes were small in incidence or severity and no particular cell- or spermatogenic stage specificity was observed. As reported in literature, tubular atrophy in the testes, even more extensive, can sometimes be seen as background finding in young adult rats (Creasy, 2011). Although an effect of the treatment cannot completely be discounted, the minor changes in the testes were more likely to be considered as background changes.
- A mammary adenocarcinoma was detected in 1 female at 300 mg/kg/day. This tumour was considered incidental based on the occurrence in a single animals and the lack on any proliferative changes in the mammary gland in the other treated animals. Although mammary adenocarcinomas are uncommon in young rats, they can occasionally occur spontaneously even at an early age, as reported in literature.
There was no evidence of test article related changes in the other examined tissues.
OTHER FINDINGS (PARENTAL ANIMALS)
Two females in the Control group and one female dosed at 300 mg/kg/day failed to litter, and were found to have no sign of any implantations pre- or post-staining on Day 25 after mating.
VIABILITY (OFFSPRING)
There was no effect of parental treatment with the test substance at 100 or 300 mg/kg bw/day on mean number of implantations, live litter size on Day 1 and offspring survival up to Day 7 of age. At 1000 mg/kg/day, the mean number of implantations showed no adverse effect of parental treatment but the post-implantation survival index (86.1% ) was slightly lower than in Controls (94.4%) and the other study groups. This resulted in marginally low total and live litter sizes. However, none of the differences attained statistical significance, and the post-implantation survival index was within the recent background control range (lowest value 84.9%): therefore no effect of treatment was inferred.
CLINICAL SIGNS (OFFSPRING)
The general appearance and behaviour of the offspring were not affected by maternal treatment.
BODY WEIGHT (OFFSPRING)
Offspring bodyweight on Day 1 of age and subsequent bodyweight gain up to Day 7 of age was similar to control values for the litters of females receiving the test substance at 100, 300 or 1000 mg/kg/day.
GROSS PATHOLOGY (OFFSPRING)
Macroscopic examination of offspring killed at scheduled termination on Day 7 of age revealed no abnormalities.
OTHER FINDINGS (OFFSPRING):
There was no effect of parental treatment with the test substance on sex ratio.
Effect on fertility: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- One study available.
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Effects on developmental toxicity
Description of key information
In a reliable pre-natal developmental toxicity study conducted on a structurally similar substance according to relevant OECD guidelines there were no adverse effects on developmental toxicity parameters and the NOAEL/NOEL is considered to be >1000 mg/kg bw/day (the highest dose tested).
Link to relevant study records
- Endpoint:
- developmental toxicity
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Read-across to K1 study therefore K2 is the maximum Klimisch value.
- Justification for type of information:
- Read-across approach - see read-across justification in section 13.
- Reason / purpose for cross-reference:
- read-across source
- Species:
- rat
- Strain:
- Sprague-Dawley
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: breeder: Janvier, le Genest-Saint-Isle, France
- Age at the beginning of the treatment period: the animals were 10-11 weeks old
- Mean body weight at the beginning of the treatment period: the animals had a mean body weight of 296 g (range: 245 g to 358 g)
- Fasting period before study: no
- Housing: the animals were individually housed in polycarbonate cages (Tecniplast 2154, 940 cm2) with stainless steel lids and containing autoclaved sawdust
- Diet: SSNIFF R/M-H pelleted diet (free access)
- Water: tap water filtered with a 0.22 µm filter (free access)
- Acclimation period: for a period of 4 or 5 days before the beginning of the treatment period.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 2°C
- Humidity (%): 50 ± 20%
- Air changes (per hr): about 8 to 15 cycles/hour of filtered, non-recycled air
- Photoperiod (hrs dark / hrs light): 12 h/12 h.
IN-LIFE DATES: 11 September 2017 to 16 October 2017. - Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on exposure:
- PREPARATION
The test item was administered as a suspension in the vehicle. The test item was ground to a fine powder, using a mortar and pestle, and then mixed with the required quantity of vehicle.
The test item dose formulations were prepared daily and were delivered to the study room at room temperature and protected from light.
This preparation process was validated for a range of concentrations covering the lowest and highest concentrations used in this study.
.
VEHICLE
- Justification for use and choice of vehicle (if other than water): homogeneous suspensions were obtained with corn oil as a vehicle
- Concentration in vehicle: 20, 60 and 200 mg/ml
- Amount of vehicle (if gavage): 5 ml/kg bw - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Type of method: High Performance Liquid Chromatography with tandem Mass Spectrometry detection (LC/MS MS)
Test item concentrations: the test item concentrations in the administered dose formulations analyzed on Study Day 5, in study Week 4 and instudy week 5 of the treatment period, were within an acceptable range of variation (-12.1% to +6.0%) when compared to the nominal values (± 15% required).
Homogeneity: The dose formulations containing the test item and prepared at 10 mg/mL and 200 mg/mL in corn oil were found to be homogeneous at room temperature and protected from light.
Stability: UVCB, dose formulation prepared daily - Details on mating procedure:
- Impregnation procedure: purchased time-mated females
Females arrived on Day 1 or 2 post-coitum - Duration of treatment / exposure:
- Days 6 to 20 post-coitum
- Frequency of treatment:
- Daily
- Dose / conc.:
- 100 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 300 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 24 females
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Rationale for dose selection:
The dose levels were selected on the basis of the results of a OECD 421 study (reproduction/developmental toxicity screening study in the Sprague-Dawley rat by oral gavage administration), where the NOAEL was set at 1000 mg/kg/day. During the first week of treatment, test item treatment-related reductions in body weight gain were apparent in all groups of treated females but the animals quickly recovered to show normal growth patterns through the rest of the study.
Therefore, 1000 mg/kg/day was selected as the high-dose level. The low-dose and mid dose were selected using a ratio representing approximately a 3-fold interval (i.e. 100 and 300 mg/kg/day).
- Rationale for animal assignment: computerized stratification procedure. - Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: each animal was checked for mortality and morbidity once a day before the treatment period and at least twice a day during the treatment period, including weekends.
CLINICAL OBSERVATIONS:Yes
- Time schedule: from arrival, each animal was observed once a day as part of the routine examinations. From the start of the treatment period, each animal was observed once a day, at approximately the same time for the recording of clinical signs.
BODY WEIGHT: Yes
- Time schedule: the body weight of each female was recorded on Days 2, 4, 6, 9, 12, 15, 18 and 21 post-coitum
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
The quantity of food consumed by each female was recorded for the following intervals: Days 2-4, 4-6, 6-9, 9-12, 12-15, 15-18 and 18-21 post-coitum
WATER CONSUMPTION: No
POST-MORTEM MACROSCOPIC EXAMINATION: Yes
- Sacrifice on Day 21 post-coitum.
- Examined: principal thoracic and abdominal organs. - Ovaries and uterine content:
- The ovaries and uterine content were examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
The weight of the gravid uterus was recorded for each pregnant female (with at least one live fetus) at hysterectomy.
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes
- Other:
- Number and distribution of dead and live fetuses,
- Number and distribution of uterine scars (uterine implantation without implant)
The following classification was used to record:
. uterine scar: uterine implantation without implant,
. early resorption: evidence of implant without recognizable embryo,
. late resorption: dead embryo or fetus with degenerative changes,
. dead fetus: dead fetus with no degenerative changes. - Fetal examinations:
- - External examinations: Yes: all fetuses per litter
- Soft tissue examinations: Yes: half fetuses per litter
- Skeletal examinations: Yes: half fetuses per litter
- Head examinations: Yes: half fetuses per litter
- Other: number of dead and alive fetuses , body weight and sex of fetuses - Statistics:
- Data were compared by one-way analysis of variance and Dunnett test (mean values being considered as normally distributed and variances being considered as homogeneous) or by Fisher’s exact probability test (proportions).
- Indices:
- The following parameters were calculated:
For each pregnant female:
- Body weight change for different intervals
- Net body weight (presented as carcass weight) = Body weight on Day 21 post-coitum - gravid uterine weight
- Net body weight change = Body weight on Day 21 post-coitum - body weight on Day 6 post-coitum - gravid uterine weight%
For each litter:
- Total number of resorptions = Sum of uterine scars + early resorptions + late resorptions
- Total number of dead fetuses = Sum of dead fetuses
- % of dead fetuses per litter = (Total number of dead fetuses / Number of implantation sites) x 100
- Total number of live fetuses = Sum of live male + live female fetuses
- % of live fetuses per litter = (Total number of live fetuses / Number of implantation sites) x 100
- % of pre-implantation loss = (Number of corpora lutea - Number of implantations / Number of corpora lutea) x 100
- % of post-implantation loss = (Number of implantation sites - Number of live fetuses / Number of implantation sites) x 100
- Average fetal body weight= Sum of individual fetal weights / Number of live fetuses
For each group:
- % of pre-implantation loss relative to the number of corpora lutea (mean of pre-implantation loss per litter)
- % of live fetuses and % of dead fetuses (relative to total number of fetuses)
- Mean % of male fetuses per litte
- Mean and standard deviations and % relative to the number of implantation sites: resorptions plus, uterine scars, uterine scars, early resorptions, late
resorptions,
- % of post-implantation loss relative to the number of implantation sites (mean of post-implantation loss per litter), % of dams affected.
- Historical control data:
- See attached document
- Clinical signs:
- effects observed, non-treatment-related
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- effects observed, non-treatment-related
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- not examined
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- no effects observed
- Description (incidence and severity):
- There were no effects on mean carcass weight, mean gravid uterus weight, or mean net body weight change.
- Details on results:
- CLINICAL SIGNS AND MORTALITY
There was no mortality observed during the study.
There were no test item-related clinical signs. Clinical signs seen at 100 and 300 mg/kg/day (cutaneous lesion, mass on mammary gland and scabs) were without dose-relationship and observed in isolated animals (3 and 1 animals at 100 and 300 mg/kg bw respectively).
BODY WEIGHT AND WEIGHT CHANGE (cf table 7.8.2/1 in chapter any other information on results)
There were no effects on mean body weight and mean body weight change.
FOOD CONSUMPTION
There were no treatment related changes on food consumption.
GROSS PATHOLOGY
There were no test item-related necropsy findings.
The mammary gland mass seen at 100 mg/kg/day (female L20663) and the mass on one placenta at 300 mg/kg/day (female L20676) were considered to be incidental in absence of dose-relationship and as it was noted in isolated animals.
OTHER EFFECTS (cf table 7.8.2/2 in chapter any other information on results)
There were no effects on mean carcass weight, mean gravid uterus weight, or mean net body weight change. - Pre- and post-implantation loss:
- effects observed, non-treatment-related
- Total litter losses by resorption:
- effects observed, non-treatment-related
- Early or late resorptions:
- no effects observed
- Dead fetuses:
- no effects observed
- Changes in pregnancy duration:
- not examined
- Description (incidence and severity):
- Migrated Data from removed field(s)
Field "Effects on pregnancy duration" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsMaternalAnimals.MaternalDevelopmentalToxicity.EffectsOnPregnancyDuration): not examined - Changes in number of pregnant:
- no effects observed
- Details on maternal toxic effects:
- PRE AND POST IMPLANTATION LOSS (cf table 7.8.2/3 in chapter any other information on results)
There were no test item-related effects on pre and post implantation losses at any dose-level.
At 1000 mg/kg/day, the 100% of post-implantation loss noted in female L20708 induced an increase of the mean percentage of post-implantation loss in this dose group (11.7% compared to 6.4% in the control group). This was considered to be incidental and due to the fact that female L20708 had only one corpora lutea. When excluding L20708 data, the mean percentage of post-implantation loss in the 1000 mg/kg bw/day group was 7.6%
TOTAL LITTER LOSSES BY RESORPTION (cf table 7.8.2/3 in chapter any other information on results)
At 1000 mg/kg/day, a total litter loss occured in female L20708 but this was considered incidental as this female had only one implantation site with one uterine scar. No other total litter losses were observed whatever the dose levels.
EARLY OR LATES RESORPTIONS (cf table 7.8.2/3 in chapter any other information on results)
There were no test item-related effects on early or late resorptions.
DEAD FETUSES (cf table 7.8.2/3 in chapter any other information on results)
There were no dead fetuses.
CHANGES IN NUMBER OF PREGNANT (cf table 7.8.2/3 in chapter any other information on results)
At hysterectomy on Day 21 post-coitum., there were 24/24, 24/24, 23/24 and 23/24 pregnant dams in the groups treated at 0, 100, 300 or 1000 mg/kg/day, respectively. - Key result
- Dose descriptor:
- NOEL
- Effect level:
- >= 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Key result
- Abnormalities:
- no effects observed
- Fetal body weight changes:
- no effects observed
- Description (incidence and severity):
- Migrated Data from removed field(s)
Field "Fetal/pup body weight changes" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsFetuses.FetalPupBodyWeightChanges): not specified - Reduction in number of live offspring:
- no effects observed
- Changes in sex ratio:
- no effects observed
- Changes in litter size and weights:
- no effects observed
- Changes in postnatal survival:
- not examined
- External malformations:
- no effects observed
- Skeletal malformations:
- no effects observed
- Visceral malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- See tables 5 and 6.
The visceral variations were considered to be incidental as there was no dose-relationship, they were within Historical Control Data, differences from controls or Historical control maximum were slight, and/or they were noted in single fetuses.
The malformations observed at 100 and 1000 mg/kg/day were considered to be unlikely related to the test item treatment as they were noted in isolated fetuses and/or without dose-relationship. - Details on embryotoxic / teratogenic effects:
- FETAL BODY WEIGHT (cf table 7.8.2/4 in chapter any other information on results)
There were no effects on mean fetal body weight.
REDUCTION IN NUMBER OF LIVE FETUSES (cf table 7.8.2/3 in chapter any other information on results)
There were no reduction in number of live fetuses compared to controls.
CHANGE IN SEX RATIO (cf table 7.8.2/4 in chapter any other information on results)
There were no effects on mean percentage of male fetuses.
CHANGE IN LITTER SIZE and WEIGHTS (cf tables 7.8.2/3 and 7.8.2/4 in chapter any other information on results)
There were no changes in litter size and weights compared to controls
EXTERNAL MALFORMATIONS:
There were no external malformations in test item treated groups.
SKELETAL MALFORMATIONS (cf tables 7.8.2/5 and 7.8.2/6 in chapter any other information on results and pdf file in attached background material)
There were no fetal skeletal malformations in test item-treated groups.
Fetal skeletal variations included extra sternebral ossification sites, misshapen sternebrae and unossified distal phalanx of the forepaws were observed at litter incidence higher than controls. None of them were attributed to treatment as their incidences were not dose-related, isolated and the fetal incidences were lower than or close to those of controls.
VISCERAL MALFORMATIONS (cf tables 7.8.2/7 in chapter any other information on results and historical data in attached background material)
In the 100 mg/kg bw/day group, kidneys were absent in 0.7% of the fetuses. In the 1000 mg/kg bw/day group, aortic arch was absent in 0.8% of the fetuses. These malformations were considered to be unlikely related to the test item treatment as they were noted in isolated fetuses without dose-relationship.
Visceral variations included dilated renal pelvis, dilated ureters, lack or short (innominate) arteries and reddish foci in thymus. They were all considered to be incidental:
Dilated renal pelvis were not dose-related and in within fetal incidence of controls. Dilated ureters were not dose-related and within fetal and litter incidences of historical control data. At 1000 mg/kg bw/day, lack of (innominate) arteries were slightly above controls but within fetal and litter incidences of historical control data. Short (innominate) arteries were similar to fetal and litter incidences of controls. Reddish foci in thymus were not dose-related and observed in a single fetus of the 100 and 300 mg/kg bw/day groups. - Key result
- Dose descriptor:
- NOEL
- Effect level:
- >= 1 000 mg/kg bw/day
- Based on:
- test mat.
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Key result
- Abnormalities:
- no effects observed
- Key result
- Developmental effects observed:
- no
- Conclusions:
- The No Observed Effect Level (NOEL) for maternal parameters and for embryo-fetal development was considered to be 1000 mg/kg/day (highest dose employed) in absence of substance-related effects in the study.
- Executive summary:
In a prenatal development toxicity study performed according to OECD 414 and in compliance with Good Laboratory Practice, the objective was to evaluate the potential toxic effects of the test substance on the pregnant female rat and on embryonic and fetal development, following oral administration (gavage) from Day 6 to Day 20 post-coitum, inclusive.
Three groups of 24 time-mated female rats received the test substance at doses of 100, 300 or 1000 mg/kg bw /day from Day 6 to 20 post-coitum. A similarly constituted Control group received the vehicle, corn oil, at the same dose volume throughout the same period. Test substance concentration was checked four times in formulations given to the animals
Animals were killed on Day 21 of gestation for reproductive assessment and fetal examination.
Clinical observations, bodyweight and food consumption were monitored. Adult females were examined macroscopically at necropsy on Day 21 of gestation and the numbers of corpora lutea, implantations, early and late resorptions, and live and dead fetuses were recorded. All fetuses were weighed, sexed and examined for external, soft tissue and skeletal abnormalities.
The substance concentrations in the analyzed dose formulations were within an acceptable range of variation when compared to the nominal values (± 15% required), with the exception of formulations administered on Day 6 post coitum (Study Day 1) for 4/24 females per group (between -19.8% and -16.6%). This marginal underdosing was considered to have no impact on the study as there were no major differences in results between these females and the other of the same groups at the end of the study.
At hysterectomy on Day 21 post-coitum., there were 24/24, 24/24, 23/24 and 22/24 pregnant dams with live fetuses in the groups treated at 0,100, 300 or 1000 mg/kg/day,respectively.
There were no test item treatment-related effects in the dams in terms of mortality, clinical signs, necropsy findings, body weight, food consumption, carcass weight, gravid uterus weight, net body weight change, or hysterectomy data. There were no substance treatment-related effects in the litters in terms of sex ratio, fetal body weight, external, visceral and skeletal variations or malformations or cartilage findings.
The No Observed Effect Level (NOEL) for maternal parameters and for embryo-fetal development was considered to be 1000 mg/kg/day (highest dose employed) in absence of treatment related effects in the study.
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 17 August 2017 - 16 October 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Version / remarks:
- 22 January 2001
- Deviations:
- yes
- Remarks:
- See for details Any Other information on Materials and Methods
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: breeder: Janvier, le Genest-Saint-Isle, France
- Age at the beginning of the treatment period: the animals were 10-11 weeks old
- Mean body weight at the beginning of the treatment period: the animals had a mean body weight of 296 g (range: 245 g to 358 g)
- Fasting period before study: no
- Housing: the animals were individually housed in polycarbonate cages (Tecniplast 2154, 940 cm2) with stainless steel lids and containing autoclaved sawdust
- Diet: SSNIFF R/M-H pelleted diet (free access)
- Water: tap water filtered with a 0.22 µm filter (free access)
- Acclimation period: for a period of 4 or 5 days before the beginning of the treatment period.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 2°C
- Humidity (%): 50 ± 20%
- Air changes (per hr): about 8 to 15 cycles/hour of filtered, non-recycled air
- Photoperiod (hrs dark / hrs light): 12 h/12 h.
IN-LIFE DATES: 11 September 2017 to 16 October 2017. - Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on exposure:
- PREPARATION
The test item was administered as a suspension in the vehicle. The test item was ground to a fine powder, using a mortar and pestle, and then mixed with the required quantity of vehicle.
The test item dose formulations were prepared daily and were delivered to the study room at room temperature and protected from light.
This preparation process was validated for a range of concentrations covering the lowest and highest concentrations used in this study.
.
VEHICLE
- Justification for use and choice of vehicle (if other than water): homogeneous suspensions were obtained with corn oil as a vehicle
- Concentration in vehicle: 20, 60 and 200 mg/ml
- Amount of vehicle (if gavage): 5 ml/kg bw - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Type of method: High Performance Liquid Chromatography with tandem Mass Spectrometry detection (LC/MS MS)
Test item concentrations: the test item concentrations in the administered dose formulations analyzed on Study Day 5, in study Week 4 and instudy week 5 of the treatment period, were within an acceptable range of variation (-12.1% to +6.0%) when compared to the nominal values (± 15% required).
Homogeneity: The dose formulations containing the test item and prepared at 10 mg/mL and 200 mg/mL in corn oil were found to be homogeneous at room temperature and protected from light.
Stability: UVCB, dose formulation prepared daily - Details on mating procedure:
- Impregnation procedure: purchased time-mated females
Females arrived on Day 1 or 2 post-coitum - Duration of treatment / exposure:
- Days 6 to 20 post-coitum
- Frequency of treatment:
- Daily
- Dose / conc.:
- 100 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 300 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 24 females
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Rationale for dose selection:
The dose levels were selected on the basis of the results of a OECD 421 study (reproduction/developmental toxicity screening study in the Sprague-Dawley rat by oral gavage administration), where the NOAEL was set at 1000 mg/kg/day. During the first week of treatment, test item treatment-related reductions in body weight gain were apparent in all groups of treated females but the animals quickly recovered to show normal growth patterns through the rest of the study.
Therefore, 1000 mg/kg/day was selected as the high-dose level. The low-dose and mid dose were selected using a ratio representing approximately a 3-fold interval (i.e. 100 and 300 mg/kg/day).
- Rationale for animal assignment: computerized stratification procedure. - Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: each animal was checked for mortality and morbidity once a day before the treatment period and at least twice a day during the treatment period, including weekends.
CLINICAL OBSERVATIONS:Yes
- Time schedule: from arrival, each animal was observed once a day as part of the routine examinations. From the start of the treatment period, each animal was observed once a day, at approximately the same time for the recording of clinical signs.
BODY WEIGHT: Yes
- Time schedule: the body weight of each female was recorded on Days 2, 4, 6, 9, 12, 15, 18 and 21 post-coitum
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
The quantity of food consumed by each female was recorded for the following intervals: Days 2-4, 4-6, 6-9, 9-12, 12-15, 15-18 and 18-21 post-coitum
WATER CONSUMPTION: No
POST-MORTEM MACROSCOPIC EXAMINATION: Yes
- Sacrifice on Day 21 post-coitum.
- Examined: principal thoracic and abdominal organs. - Ovaries and uterine content:
- The ovaries and uterine content were examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
The weight of the gravid uterus was recorded for each pregnant female (with at least one live fetus) at hysterectomy.
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes
- Other:
- Number and distribution of dead and live fetuses,
- Number and distribution of uterine scars (uterine implantation without implant)
The following classification was used to record:
. uterine scar: uterine implantation without implant,
. early resorption: evidence of implant without recognizable embryo,
. late resorption: dead embryo or fetus with degenerative changes,
. dead fetus: dead fetus with no degenerative changes. - Fetal examinations:
- - External examinations: Yes: all fetuses per litter
- Soft tissue examinations: Yes: half fetuses per litter
- Skeletal examinations: Yes: half fetuses per litter
- Head examinations: Yes: half fetuses per litter
- Other: number of dead and alive fetuses , body weight and sex of fetuses - Statistics:
- Data were compared by one-way analysis of variance and Dunnett test (mean values being considered as normally distributed and variances being considered as homogeneous) or by Fisher’s exact probability test (proportions).
- Indices:
- The following parameters were calculated:
For each pregnant female:
- Body weight change for different intervals
- Net body weight (presented as carcass weight) = Body weight on Day 21 post-coitum - gravid uterine weight
- Net body weight change = Body weight on Day 21 post-coitum - body weight on Day 6 post-coitum - gravid uterine weight%
For each litter:
- Total number of resorptions = Sum of uterine scars + early resorptions + late resorptions
- Total number of dead fetuses = Sum of dead fetuses
- % of dead fetuses per litter = (Total number of dead fetuses / Number of implantation sites) x 100
- Total number of live fetuses = Sum of live male + live female fetuses
- % of live fetuses per litter = (Total number of live fetuses / Number of implantation sites) x 100
- % of pre-implantation loss = (Number of corpora lutea - Number of implantations / Number of corpora lutea) x 100
- % of post-implantation loss = (Number of implantation sites - Number of live fetuses / Number of implantation sites) x 100
- Average fetal body weight= Sum of individual fetal weights / Number of live fetuses
For each group:
- % of pre-implantation loss relative to the number of corpora lutea (mean of pre-implantation loss per litter)
- % of live fetuses and % of dead fetuses (relative to total number of fetuses)
- Mean % of male fetuses per litte
- Mean and standard deviations and % relative to the number of implantation sites: resorptions plus, uterine scars, uterine scars, early resorptions, late
resorptions,
- % of post-implantation loss relative to the number of implantation sites (mean of post-implantation loss per litter), % of dams affected.
- Historical control data:
- See attached document
- Clinical signs:
- effects observed, non-treatment-related
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- effects observed, non-treatment-related
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- not examined
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- no effects observed
- Description (incidence and severity):
- There were no effects on mean carcass weight, mean gravid uterus weight, or mean net body weight change.
- Details on results:
- CLINICAL SIGNS AND MORTALITY
There was no mortality observed during the study.
There were no test item-related clinical signs. Clinical signs seen at 100 and 300 mg/kg/day (cutaneous lesion, mass on mammary gland and scabs) were without dose-relationship and observed in isolated animals (3 and 1 animals at 100 and 300 mg/kg bw respectively).
BODY WEIGHT AND WEIGHT CHANGE (cf table 7.8.2/1 in chapter any other information on results)
There were no effects on mean body weight and mean body weight change.
FOOD CONSUMPTION
There were no treatment related changes on food consumption.
GROSS PATHOLOGY
There were no test item-related necropsy findings.
The mammary gland mass seen at 100 mg/kg/day (female L20663) and the mass on one placenta at 300 mg/kg/day (female L20676) were considered to be incidental in absence of dose-relationship and as it was noted in isolated animals.
OTHER EFFECTS (cf table 7.8.2/2 in chapter any other information on results)
There were no effects on mean carcass weight, mean gravid uterus weight, or mean net body weight change. - Pre- and post-implantation loss:
- effects observed, non-treatment-related
- Total litter losses by resorption:
- effects observed, non-treatment-related
- Early or late resorptions:
- no effects observed
- Dead fetuses:
- no effects observed
- Changes in pregnancy duration:
- not examined
- Description (incidence and severity):
- Migrated Data from removed field(s)
Field "Effects on pregnancy duration" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsMaternalAnimals.MaternalDevelopmentalToxicity.EffectsOnPregnancyDuration): not examined - Changes in number of pregnant:
- no effects observed
- Details on maternal toxic effects:
- PRE AND POST IMPLANTATION LOSS (cf table 7.8.2/3 in chapter any other information on results)
There were no test item-related effects on pre and post implantation losses at any dose-level.
At 1000 mg/kg/day, the 100% of post-implantation loss noted in female L20708 induced an increase of the mean percentage of post-implantation loss in this dose group (11.7% compared to 6.4% in the control group). This was considered to be incidental and due to the fact that female L20708 had only one corpora lutea. When excluding L20708 data, the mean percentage of post-implantation loss in the 1000 mg/kg bw/day group was 7.6%
TOTAL LITTER LOSSES BY RESORPTION (cf table 7.8.2/3 in chapter any other information on results)
At 1000 mg/kg/day, a total litter loss occured in female L20708 but this was considered incidental as this female had only one implantation site with one uterine scar. No other total litter losses were observed whatever the dose levels.
EARLY OR LATES RESORPTIONS (cf table 7.8.2/3 in chapter any other information on results)
There were no test item-related effects on early or late resorptions.
DEAD FETUSES (cf table 7.8.2/3 in chapter any other information on results)
There were no dead fetuses.
CHANGES IN NUMBER OF PREGNANT (cf table 7.8.2/3 in chapter any other information on results)
At hysterectomy on Day 21 post-coitum., there were 24/24, 24/24, 23/24 and 23/24 pregnant dams in the groups treated at 0, 100, 300 or 1000 mg/kg/day, respectively. - Key result
- Dose descriptor:
- NOEL
- Effect level:
- >= 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Key result
- Abnormalities:
- no effects observed
- Fetal body weight changes:
- no effects observed
- Description (incidence and severity):
- Migrated Data from removed field(s)
Field "Fetal/pup body weight changes" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsFetuses.FetalPupBodyWeightChanges): not specified - Reduction in number of live offspring:
- no effects observed
- Changes in sex ratio:
- no effects observed
- Changes in litter size and weights:
- no effects observed
- Changes in postnatal survival:
- not examined
- External malformations:
- no effects observed
- Skeletal malformations:
- no effects observed
- Visceral malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- See tables 5 and 6.
The visceral variations were considered to be incidental as there was no dose-relationship, they were within Historical Control Data, differences from controls or Historical control maximum were slight, and/or they were noted in single fetuses.
The malformations observed at 100 and 1000 mg/kg/day were considered to be unlikely related to the test item treatment as they were noted in isolated fetuses and/or without dose-relationship. - Details on embryotoxic / teratogenic effects:
- FETAL BODY WEIGHT (cf table 7.8.2/4 in chapter any other information on results)
There were no effects on mean fetal body weight.
REDUCTION IN NUMBER OF LIVE FETUSES (cf table 7.8.2/3 in chapter any other information on results)
There were no reduction in number of live fetuses compared to controls.
CHANGE IN SEX RATIO (cf table 7.8.2/4 in chapter any other information on results)
There were no effects on mean percentage of male fetuses.
CHANGE IN LITTER SIZE and WEIGHTS (cf tables 7.8.2/3 and 7.8.2/4 in chapter any other information on results)
There were no changes in litter size and weights compared to controls
EXTERNAL MALFORMATIONS:
There were no external malformations in test item treated groups.
SKELETAL MALFORMATIONS (cf tables 7.8.2/5 and 7.8.2/6 in chapter any other information on results and pdf file in attached background material)
There were no fetal skeletal malformations in test item-treated groups.
Fetal skeletal variations included extra sternebral ossification sites, misshapen sternebrae and unossified distal phalanx of the forepaws were observed at litter incidence higher than controls. None of them were attributed to treatment as their incidences were not dose-related, isolated and the fetal incidences were lower than or close to those of controls.
VISCERAL MALFORMATIONS (cf tables 7.8.2/7 in chapter any other information on results and historical data in attached background material)
In the 100 mg/kg bw/day group, kidneys were absent in 0.7% of the fetuses. In the 1000 mg/kg bw/day group, aortic arch was absent in 0.8% of the fetuses. These malformations were considered to be unlikely related to the test item treatment as they were noted in isolated fetuses without dose-relationship.
Visceral variations included dilated renal pelvis, dilated ureters, lack or short (innominate) arteries and reddish foci in thymus. They were all considered to be incidental:
Dilated renal pelvis were not dose-related and in within fetal incidence of controls. Dilated ureters were not dose-related and within fetal and litter incidences of historical control data. At 1000 mg/kg bw/day, lack of (innominate) arteries were slightly above controls but within fetal and litter incidences of historical control data. Short (innominate) arteries were similar to fetal and litter incidences of controls. Reddish foci in thymus were not dose-related and observed in a single fetus of the 100 and 300 mg/kg bw/day groups. - Key result
- Dose descriptor:
- NOEL
- Effect level:
- >= 1 000 mg/kg bw/day
- Based on:
- test mat.
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Key result
- Abnormalities:
- no effects observed
- Key result
- Developmental effects observed:
- no
- Conclusions:
- The No Observed Effect Level (NOEL) for maternal parameters and for embryo-fetal development was considered to be 1000 mg/kg/day (highest dose employed) in absence of substance-related effects in the study.
- Executive summary:
In a prenatal development toxicity study performed according to OECD 414 and in compliance with Good Laboratory Practice, the objective was to evaluate the potential toxic effects of the test substance on the pregnant female rat and on embryonic and fetal development, following oral administration (gavage) from Day 6 to Day 20 post-coitum, inclusive.
Three groups of 24 time-mated female rats received the test substance at doses of 100, 300 or 1000 mg/kg bw /day from Day 6 to 20 post-coitum. A similarly constituted Control group received the vehicle, corn oil, at the same dose volume throughout the same period. Test substance concentration was checked four times in formulations given to the animals
Animals were killed on Day 21 of gestation for reproductive assessment and fetal examination.
Clinical observations, bodyweight and food consumption were monitored. Adult females were examined macroscopically at necropsy on Day 21 of gestation and the numbers of corpora lutea, implantations, early and late resorptions, and live and dead fetuses were recorded. All fetuses were weighed, sexed and examined for external, soft tissue and skeletal abnormalities.
The substance concentrations in the analyzed dose formulations were within an acceptable range of variation when compared to the nominal values (± 15% required), with the exception of formulations administered on Day 6 post coitum (Study Day 1) for 4/24 females per group (between -19.8% and -16.6%). This marginal underdosing was considered to have no impact on the study as there were no major differences in results between these females and the other of the same groups at the end of the study.
At hysterectomy on Day 21 post-coitum., there were 24/24, 24/24, 23/24 and 22/24 pregnant dams with live fetuses in the groups treated at 0,100, 300 or 1000 mg/kg/day,respectively.
There were no test item treatment-related effects in the dams in terms of mortality, clinical signs, necropsy findings, body weight, food consumption, carcass weight, gravid uterus weight, net body weight change, or hysterectomy data. There were no substance treatment-related effects in the litters in terms of sex ratio, fetal body weight, external, visceral and skeletal variations or malformations or cartilage findings.
The No Observed Effect Level (NOEL) for maternal parameters and for embryo-fetal development was considered to be 1000 mg/kg/day (highest dose employed) in absence of treatment related effects in the study.
Referenceopen allclose all
Table 7.8.2/1: Mean Body weight and mean body weight change (g) in pregnant females with live concepti:
Dose level (mg/kg/day) |
0 |
100 |
300 |
1000 |
Body weight |
|
|
|
|
Day 6 post-coitum |
299 |
295 |
295 |
297 |
|
|
-1 |
-1 |
-1 |
Day 21 post-coitum |
450 |
442 |
443 |
453 |
|
|
-2 |
-2 |
+1 |
Body weight change |
|
|
|
|
Days 6 - 21 post-coitum |
+151 |
+147 |
+147 |
+156 |
in italic: differences from controls (%)
Table 7.8.2/2: Mean gravid uterus, mean carcass weights and mean net body weight change (g) in pregnant females with live concepti:
Dose level (mg/kg/day) |
0 |
100 |
300 |
1000 |
Gravid uterus weight |
99.6 |
98.9 |
101.8 |
105.0 |
Carcass weighta |
350 |
343 |
341 |
348 |
Net body weight change from Day 6post-coitum |
51.5 |
48.2 |
45.2 |
50.8 |
a: values rounded to three significant digits.
Table 7.8.2/3: Hysterectomy data
Dose (mg/kg/day) |
|
0 |
100 |
300 |
1000 |
Pregnant Females Alive at Term |
N |
24 |
24 |
23 |
23 |
With Total Resorptions |
N |
0 |
0 |
0 |
1* |
With all Dead Fetuses |
N |
0 |
0 |
0 |
0 |
With Live Fetuses |
N |
24 |
24 |
23 |
22 |
Corpora Lutea |
TOTAL MEAN SD |
344 14.3 2.5 |
353 14.7 2.4 |
313 13.6 2.1 |
320 13.9 3.1 |
N° per animal |
|||||
Implantation Sites |
TOTAL MEAN SD |
314 13.1 2.2 |
317 13.2 2.4 |
298 13.0 2.2 |
303 13.2 3.0 |
N° per animal |
|||||
|
|||||
Preimplantation Loss |
MEAN % SD |
8.4 9.6 |
10.0 11.2 |
4.8 5.2 |
5.0 5.1 |
|
|||||
Fetuses |
TOTAL MEAN SD |
295 12.3 2.6 |
296 12.3 2.3 |
283 12.3 2.2 |
279 12.1 3.2 |
N° per animal |
|||||
|
|||||
Live Fetuses |
TOTAL MEAN SD MEAN% SD |
295 12.3 2.6 93.6 9.4 |
296 12.3 2.3 93.5 5.7 |
283 12.3 2.2 95.7 11.2 |
279 12.1 3.2 88.3 21.6 |
Dead Fetuses |
TOTAL MEAN % SD |
0 0.0 0.0 |
0 0.0 0.0 |
0 0.0 0.0 |
0 0.0 0.0 |
Resorptions+Scars |
TOTAL
MEAN SD |
19 6.1
0.8 1.2 |
21 6.6
0.9 0.7 |
15 5.0
0.7 1.9 |
24 7.9
1.0 1.3 |
% of implantation sites |
|||||
N° per animal |
|||||
|
|||||
Implant Scars |
TOTAL
MEAN SD |
0 0.0
0.0 0.0 |
0 0.0
0.0 0.0 |
0 0.0
0.0 0.0 |
1 0.3
0.0 0.2 |
% of implantation sites |
|||||
N° per animal |
|||||
|
|||||
Resorptions: early |
TOTAL
MEAN SD |
18 5.7
0.8 1.2 |
18 5.7
0.8 0.7 |
15 5.0
0.7 1.9 |
20 6.6
0.9 1.4 |
% of implantation sites |
|||||
N° per animal |
|||||
|
|||||
Resorptions: late |
TOTAL
MEAN SD |
1 0.3
0.0 0.2 |
3 0.9
0.1 0.3 |
0 0.0
0.0 0.0 |
3 1.0
0.1 0.5 |
% of implantation sites |
|||||
N° per animal |
|||||
|
|||||
Postimplantation Loss
Dams Affected |
MEAN% SD N % |
6.4 9.4 11 45.8 |
6.5 5.7 16 66.7 |
4.3 11.2 7 30.4 |
11.7 ** 21.6 13 56.5 |
*: female L20708 **: mean of 7.6% when excluding data of female L20708
Table 7.8.2/4: Mean fetal body weight (g) and sex ratio
Dose (mg/kg/day) |
|
0 |
100 |
300 |
1000 |
Fetal Body Weight (g)/ Litter (N) |
N MEAN SD |
24 5.76 0.41 |
24 5.72 0.53 |
23 5.97 0.46 |
22 5.93 0.31 |
Males Fetuses/ Litter (N) |
N MEAN SD |
24 5.93 0.45 |
24 5.87 0.56 |
23 6.15 0.45 |
22 6.10 0.31 |
Males Fetuses |
MEAN% SD |
50.8 14.8 |
43.7 14.4 |
49.4 12.3 |
50.5 16.2 |
Table 7.8.2/5: Total fetal skeletal malformations
Dose (mg/kg/day) |
|
0 |
100 |
300 |
1000 |
Litters Evaluated |
N |
24 |
24 |
23 |
22 |
Fetuses Evaluated |
N |
154 |
154 |
146 |
146 |
Fetal Incidence |
N % |
7 4.5 |
0 0.0 |
0 0.0 |
0 0.0 |
Litter Incidence |
N % |
5 20.8 |
0 0.0 |
0 0.0 |
0 0.0 |
Affected Fetuses /Litter |
MEAN% SD |
5.3 11.1 |
0.0 0.0 |
0.0 0.0 |
0.0 0.0 |
Table 7.8.2/6: Total fetal skeletal variations
Dose (mg/kg/day) |
|
0 |
100 |
300 |
1000 |
Litters Evaluated |
N |
24 |
24 |
23 |
22 |
Fetuses Evaluated |
N |
154 |
154 |
146 |
146 |
Fetal Incidence |
N % |
113 73.4 |
113 73.4 |
94 64.4 |
99 67.8 |
Litter Incidence |
N % |
20 83.3 |
23 95.8 |
19 82.6 |
22 100 |
Affected Fetuses /Litter |
MEAN% SD |
72.9 35.8 |
72.8 29.3 |
62.1 38.6 |
67.5 25.2 |
Table 7.8.2/7: Fetal soft tissue malformations
Dose (mg/kg/day) |
|
0 |
100 |
300 |
1000 |
Litters Evaluated |
N |
24 |
24 |
23 |
22 |
Fetuses Evaluated |
N |
141 |
142 |
137 |
133 |
|
|||||
MOUTH, JAW, PALATE |
|
|
|
|
|
Litter Incidence |
N |
1 |
0 |
0 |
0 |
Fetal Incidence |
N |
1 |
0 |
0 |
0 |
|
|||||
CLEFT PALATE |
|
|
|
|
|
Fetal Incidence |
N % |
1 0.7 |
0 0.0 |
0 0.0 |
0 0.0 |
Litter Incidence |
N % |
1 4.2 |
0 0.0 |
0 0.0 |
0 0.0 |
Affected Fetuses /Litter |
MEAN % SD |
0.8 4.1 |
0.0 0.0 |
0.0 0.0 |
0.0 0.0 |
|
|||||
KIDNEYS |
|
|
|
|
|
Litter Incidence |
N |
0 |
1 |
0 |
0 |
Fetal Incidence |
N |
0 |
1 |
0 |
0 |
|
|||||
ABSENT KIDNEY |
|
|
|
|
|
Fetal Incidence |
N % |
0 0.0 |
1 0.7 |
0 0.0 |
0 0.0 |
Litter Incidence |
N % |
0 0.0 |
1 4.2 |
0 0.0 |
0 0.0 |
Affected Fetuses /Litter |
MEAN % SD |
0.0 0.0 |
0.7 3.4 |
0.0 0.0 |
0.0 0.0 |
|
|||||
VESSELS |
|
|
|
|
|
Litter Incidence |
N |
0 |
0 |
0 |
1 |
Fetal Incidence |
N |
0 |
0 |
0 |
1 |
|
|||||
ABSENT AORTIC ARCH |
|
|
|
|
|
Fetal Incidence |
N % |
0 0.0 |
0 0.0 |
0 0.0 |
1 0.8 |
Litter Incidence |
N % |
0 0.0 |
0 0.0 |
0 0.0 |
1 4.5 |
Affected Fetuses /Litter |
MEAN % SD |
0.0 0.0 |
0.0 0.0 |
0.0 0.0 |
0.6 3.0 |
|
|||||
TOTAL FETAL SOFT TISSUE MALFORMATIONS |
|
|
|
|
|
Fetal Incidence |
N % |
1 0.7 |
1 0.7 |
0 0 |
1 0.8 |
Litter Incidence |
N % |
1 4.2 |
1 4.2 |
0 0.0 |
1 4.5 |
Affected Fetuses /Litter |
MEAN % SD |
0.8 4.1 |
0.7 3.4 |
0.0 0.0 |
0.6 3.0 |
Table 7.8.2/8: Fetal soft tissue variations
Dose (mg/kg/day) |
|
0 |
100 |
300 |
1000 |
Litters Evaluated |
N |
24 |
24 |
23 |
22 |
Fetuses Evaluated |
N |
141 |
142 |
137 |
133 |
|
|||||
URETER |
|
|
|
|
|
Litter Incidence |
N |
5 |
5 |
7 |
6 |
Fetal Incidence |
N |
7 |
6 |
9 |
9 |
|
|||||
DILATED URETER |
|
|
|
|
|
Fetal Incidence |
N % |
7 5.0 |
6 4.2 |
9 6.6 |
9 6.8 |
Litter Incidence |
N % |
5 20.8 |
5 20.8 |
7 30.4 |
6 27.3 |
Affected Fetuses /Litter |
MEAN % SD |
4.9 10.8 |
4.7 11.3 |
6.1 10.2 |
6.5 12.8 |
|
|||||
KIDNEYS |
|
|
|
|
|
Litter Incidence |
N |
2 |
3 |
2 |
2 |
Fetal Incidence |
N |
3 |
3 |
2 |
2 |
|
|||||
DILATED RENAL PELVIS |
|
|
|
|
|
Fetal Incidence |
N % |
3 2.1 |
3 2.1 |
2 1.5 |
2 1.5 |
Litter Incidence |
N % |
2 8.3 |
3 12.5 |
2 8.7 |
2 9.1 |
Affected Fetuses /Litter |
MEAN % SD |
2.2 8.4 |
2.2 6.3 |
1.3 4.5 |
1.5 4.9 |
|
|||||
VESSELS |
|
|
|
|
|
Litter Incidence |
N |
3 |
2 |
2 |
4 |
Fetal Incidence |
N |
4 |
2 |
2 |
6 |
|
|||||
ABSENT INNOMINATE ARTERY |
|
|
|
|
|
Fetal Incidence |
N % |
3 2.1 |
2 1.4 |
2 1.5 |
5 3.8 |
Litter Incidence |
N % |
3 12.5 |
2 8.3 |
2 8.7 |
4 18.2 |
Affected Fetuses /Litter |
MEAN % SD |
1.9 5.1 |
1.3 4.4 |
1.2 4.1 |
3.6 8.5 |
SHORT INNOMINATE ARTERY |
|
|
|
|
|
Fetal Incidence |
N % |
1 0.7 |
0 0.0 |
0 0.0 |
1 0.8 |
Litter Incidence |
N % |
1 4.2 |
0 0.0 |
0 0.0 |
1 4.5 |
Affected Fetuses /Litter |
MEAN % SD |
0.6 2.9 |
0.0 0.0 |
0.0 0.0 |
0.8 3.6 |
|
|||||
THYMUS |
|
|
|
|
|
Litter Incidence |
N |
0 |
1 |
1 |
0 |
Fetal Incidence |
N |
0 |
1 |
1 |
0 |
|
|||||
REDDISH FOCUS |
|
|
|
|
|
Fetal Incidence |
N % |
0 0.0 |
1 0.7 |
1 0.7 |
0 0.0 |
Litter Incidence |
N % |
0 0.0 |
1 4.2 |
1 4.3 |
0 0.0 |
Affected Fetuses /Litter |
MEAN % SD |
0.0 0.0 |
0.6 2.6 |
0.7 3.5 |
0.0 0.0 |
|
|||||
TOTAL FETAL SOFT TISSUE MALFORMATIONS |
|
|
|
|
|
Fetal Incidence |
N % |
11 7.8 |
7 4.9 |
12 8.8 |
14 10.5 |
Litter Incidence |
N % |
7 29.2 |
5 20.8 |
8 34.8 |
8 36.4 |
Affected Fetuses /Litter |
MEAN % SD |
7.4 13.3 |
5.4 12.5 |
8.0 12.7 |
10.2 21.9 |
Table 7.8.2/1: Mean Body weight and mean body weight change (g) in pregnant females with live concepti:
Dose level (mg/kg/day) |
0 |
100 |
300 |
1000 |
Body weight |
|
|
|
|
Day 6 post-coitum |
299 |
295 |
295 |
297 |
|
|
-1 |
-1 |
-1 |
Day 21 post-coitum |
450 |
442 |
443 |
453 |
|
|
-2 |
-2 |
+1 |
Body weight change |
|
|
|
|
Days 6 - 21 post-coitum |
+151 |
+147 |
+147 |
+156 |
in italic: differences from controls (%)
Table 7.8.2/2: Mean gravid uterus, mean carcass weights and mean net body weight change (g) in pregnant females with live concepti:
Dose level (mg/kg/day) |
0 |
100 |
300 |
1000 |
Gravid uterus weight |
99.6 |
98.9 |
101.8 |
105.0 |
Carcass weighta |
350 |
343 |
341 |
348 |
Net body weight change from Day 6post-coitum |
51.5 |
48.2 |
45.2 |
50.8 |
a: values rounded to three significant digits.
Table 7.8.2/3: Hysterectomy data
Dose (mg/kg/day) |
|
0 |
100 |
300 |
1000 |
Pregnant Females Alive at Term |
N |
24 |
24 |
23 |
23 |
With Total Resorptions |
N |
0 |
0 |
0 |
1* |
With all Dead Fetuses |
N |
0 |
0 |
0 |
0 |
With Live Fetuses |
N |
24 |
24 |
23 |
22 |
Corpora Lutea |
TOTAL MEAN SD |
344 14.3 2.5 |
353 14.7 2.4 |
313 13.6 2.1 |
320 13.9 3.1 |
N° per animal |
|||||
Implantation Sites |
TOTAL MEAN SD |
314 13.1 2.2 |
317 13.2 2.4 |
298 13.0 2.2 |
303 13.2 3.0 |
N° per animal |
|||||
|
|||||
Preimplantation Loss |
MEAN % SD |
8.4 9.6 |
10.0 11.2 |
4.8 5.2 |
5.0 5.1 |
|
|||||
Fetuses |
TOTAL MEAN SD |
295 12.3 2.6 |
296 12.3 2.3 |
283 12.3 2.2 |
279 12.1 3.2 |
N° per animal |
|||||
|
|||||
Live Fetuses |
TOTAL MEAN SD MEAN% SD |
295 12.3 2.6 93.6 9.4 |
296 12.3 2.3 93.5 5.7 |
283 12.3 2.2 95.7 11.2 |
279 12.1 3.2 88.3 21.6 |
Dead Fetuses |
TOTAL MEAN % SD |
0 0.0 0.0 |
0 0.0 0.0 |
0 0.0 0.0 |
0 0.0 0.0 |
Resorptions+Scars |
TOTAL
MEAN SD |
19 6.1
0.8 1.2 |
21 6.6
0.9 0.7 |
15 5.0
0.7 1.9 |
24 7.9
1.0 1.3 |
% of implantation sites |
|||||
N° per animal |
|||||
|
|||||
Implant Scars |
TOTAL
MEAN SD |
0 0.0
0.0 0.0 |
0 0.0
0.0 0.0 |
0 0.0
0.0 0.0 |
1 0.3
0.0 0.2 |
% of implantation sites |
|||||
N° per animal |
|||||
|
|||||
Resorptions: early |
TOTAL
MEAN SD |
18 5.7
0.8 1.2 |
18 5.7
0.8 0.7 |
15 5.0
0.7 1.9 |
20 6.6
0.9 1.4 |
% of implantation sites |
|||||
N° per animal |
|||||
|
|||||
Resorptions: late |
TOTAL
MEAN SD |
1 0.3
0.0 0.2 |
3 0.9
0.1 0.3 |
0 0.0
0.0 0.0 |
3 1.0
0.1 0.5 |
% of implantation sites |
|||||
N° per animal |
|||||
|
|||||
Postimplantation Loss
Dams Affected |
MEAN% SD N % |
6.4 9.4 11 45.8 |
6.5 5.7 16 66.7 |
4.3 11.2 7 30.4 |
11.7 ** 21.6 13 56.5 |
*: female L20708 **: mean of 7.6% when excluding data of female L20708
Table 7.8.2/4: Mean fetal body weight (g) and sex ratio
Dose (mg/kg/day) |
|
0 |
100 |
300 |
1000 |
Fetal Body Weight (g)/ Litter (N) |
N MEAN SD |
24 5.76 0.41 |
24 5.72 0.53 |
23 5.97 0.46 |
22 5.93 0.31 |
Males Fetuses/ Litter (N) |
N MEAN SD |
24 5.93 0.45 |
24 5.87 0.56 |
23 6.15 0.45 |
22 6.10 0.31 |
Males Fetuses |
MEAN% SD |
50.8 14.8 |
43.7 14.4 |
49.4 12.3 |
50.5 16.2 |
Table 7.8.2/5: Total fetal skeletal malformations
Dose (mg/kg/day) |
|
0 |
100 |
300 |
1000 |
Litters Evaluated |
N |
24 |
24 |
23 |
22 |
Fetuses Evaluated |
N |
154 |
154 |
146 |
146 |
Fetal Incidence |
N % |
7 4.5 |
0 0.0 |
0 0.0 |
0 0.0 |
Litter Incidence |
N % |
5 20.8 |
0 0.0 |
0 0.0 |
0 0.0 |
Affected Fetuses /Litter |
MEAN% SD |
5.3 11.1 |
0.0 0.0 |
0.0 0.0 |
0.0 0.0 |
Table 7.8.2/6: Total fetal skeletal variations
Dose (mg/kg/day) |
|
0 |
100 |
300 |
1000 |
Litters Evaluated |
N |
24 |
24 |
23 |
22 |
Fetuses Evaluated |
N |
154 |
154 |
146 |
146 |
Fetal Incidence |
N % |
113 73.4 |
113 73.4 |
94 64.4 |
99 67.8 |
Litter Incidence |
N % |
20 83.3 |
23 95.8 |
19 82.6 |
22 100 |
Affected Fetuses /Litter |
MEAN% SD |
72.9 35.8 |
72.8 29.3 |
62.1 38.6 |
67.5 25.2 |
Table 7.8.2/7: Fetal soft tissue malformations
Dose (mg/kg/day) |
|
0 |
100 |
300 |
1000 |
Litters Evaluated |
N |
24 |
24 |
23 |
22 |
Fetuses Evaluated |
N |
141 |
142 |
137 |
133 |
|
|||||
MOUTH, JAW, PALATE |
|
|
|
|
|
Litter Incidence |
N |
1 |
0 |
0 |
0 |
Fetal Incidence |
N |
1 |
0 |
0 |
0 |
|
|||||
CLEFT PALATE |
|
|
|
|
|
Fetal Incidence |
N % |
1 0.7 |
0 0.0 |
0 0.0 |
0 0.0 |
Litter Incidence |
N % |
1 4.2 |
0 0.0 |
0 0.0 |
0 0.0 |
Affected Fetuses /Litter |
MEAN % SD |
0.8 4.1 |
0.0 0.0 |
0.0 0.0 |
0.0 0.0 |
|
|||||
KIDNEYS |
|
|
|
|
|
Litter Incidence |
N |
0 |
1 |
0 |
0 |
Fetal Incidence |
N |
0 |
1 |
0 |
0 |
|
|||||
ABSENT KIDNEY |
|
|
|
|
|
Fetal Incidence |
N % |
0 0.0 |
1 0.7 |
0 0.0 |
0 0.0 |
Litter Incidence |
N % |
0 0.0 |
1 4.2 |
0 0.0 |
0 0.0 |
Affected Fetuses /Litter |
MEAN % SD |
0.0 0.0 |
0.7 3.4 |
0.0 0.0 |
0.0 0.0 |
|
|||||
VESSELS |
|
|
|
|
|
Litter Incidence |
N |
0 |
0 |
0 |
1 |
Fetal Incidence |
N |
0 |
0 |
0 |
1 |
|
|||||
ABSENT AORTIC ARCH |
|
|
|
|
|
Fetal Incidence |
N % |
0 0.0 |
0 0.0 |
0 0.0 |
1 0.8 |
Litter Incidence |
N % |
0 0.0 |
0 0.0 |
0 0.0 |
1 4.5 |
Affected Fetuses /Litter |
MEAN % SD |
0.0 0.0 |
0.0 0.0 |
0.0 0.0 |
0.6 3.0 |
|
|||||
TOTAL FETAL SOFT TISSUE MALFORMATIONS |
|
|
|
|
|
Fetal Incidence |
N % |
1 0.7 |
1 0.7 |
0 0 |
1 0.8 |
Litter Incidence |
N % |
1 4.2 |
1 4.2 |
0 0.0 |
1 4.5 |
Affected Fetuses /Litter |
MEAN % SD |
0.8 4.1 |
0.7 3.4 |
0.0 0.0 |
0.6 3.0 |
Table 7.8.2/8: Fetal soft tissue variations
Dose (mg/kg/day) |
|
0 |
100 |
300 |
1000 |
Litters Evaluated |
N |
24 |
24 |
23 |
22 |
Fetuses Evaluated |
N |
141 |
142 |
137 |
133 |
|
|||||
URETER |
|
|
|
|
|
Litter Incidence |
N |
5 |
5 |
7 |
6 |
Fetal Incidence |
N |
7 |
6 |
9 |
9 |
|
|||||
DILATED URETER |
|
|
|
|
|
Fetal Incidence |
N % |
7 5.0 |
6 4.2 |
9 6.6 |
9 6.8 |
Litter Incidence |
N % |
5 20.8 |
5 20.8 |
7 30.4 |
6 27.3 |
Affected Fetuses /Litter |
MEAN % SD |
4.9 10.8 |
4.7 11.3 |
6.1 10.2 |
6.5 12.8 |
|
|||||
KIDNEYS |
|
|
|
|
|
Litter Incidence |
N |
2 |
3 |
2 |
2 |
Fetal Incidence |
N |
3 |
3 |
2 |
2 |
|
|||||
DILATED RENAL PELVIS |
|
|
|
|
|
Fetal Incidence |
N % |
3 2.1 |
3 2.1 |
2 1.5 |
2 1.5 |
Litter Incidence |
N % |
2 8.3 |
3 12.5 |
2 8.7 |
2 9.1 |
Affected Fetuses /Litter |
MEAN % SD |
2.2 8.4 |
2.2 6.3 |
1.3 4.5 |
1.5 4.9 |
|
|||||
VESSELS |
|
|
|
|
|
Litter Incidence |
N |
3 |
2 |
2 |
4 |
Fetal Incidence |
N |
4 |
2 |
2 |
6 |
|
|||||
ABSENT INNOMINATE ARTERY |
|
|
|
|
|
Fetal Incidence |
N % |
3 2.1 |
2 1.4 |
2 1.5 |
5 3.8 |
Litter Incidence |
N % |
3 12.5 |
2 8.3 |
2 8.7 |
4 18.2 |
Affected Fetuses /Litter |
MEAN % SD |
1.9 5.1 |
1.3 4.4 |
1.2 4.1 |
3.6 8.5 |
SHORT INNOMINATE ARTERY |
|
|
|
|
|
Fetal Incidence |
N % |
1 0.7 |
0 0.0 |
0 0.0 |
1 0.8 |
Litter Incidence |
N % |
1 4.2 |
0 0.0 |
0 0.0 |
1 4.5 |
Affected Fetuses /Litter |
MEAN % SD |
0.6 2.9 |
0.0 0.0 |
0.0 0.0 |
0.8 3.6 |
|
|||||
THYMUS |
|
|
|
|
|
Litter Incidence |
N |
0 |
1 |
1 |
0 |
Fetal Incidence |
N |
0 |
1 |
1 |
0 |
|
|||||
REDDISH FOCUS |
|
|
|
|
|
Fetal Incidence |
N % |
0 0.0 |
1 0.7 |
1 0.7 |
0 0.0 |
Litter Incidence |
N % |
0 0.0 |
1 4.2 |
1 4.3 |
0 0.0 |
Affected Fetuses /Litter |
MEAN % SD |
0.0 0.0 |
0.6 2.6 |
0.7 3.5 |
0.0 0.0 |
|
|||||
TOTAL FETAL SOFT TISSUE MALFORMATIONS |
|
|
|
|
|
Fetal Incidence |
N % |
11 7.8 |
7 4.9 |
12 8.8 |
14 10.5 |
Litter Incidence |
N % |
7 29.2 |
5 20.8 |
8 34.8 |
8 36.4 |
Affected Fetuses /Litter |
MEAN % SD |
7.4 13.3 |
5.4 12.5 |
8.0 12.7 |
10.2 21.9 |
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- Sufficient to address requirements.
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
No effects on reproductive performance and offspring growth and survival were observed at a dose of 1000 mg/kg bw/day in a screening study for reproductive /developmental effects performed in rats with the read-across substance bisamide (UVCB). In addition no effects were observed in a developmental toxicity study also conducted on the read-across substance. On the basis of these results, there is no justification for classification.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
